Status:
COMPLETED
Salivary dysfuncTion After Radioiodine Treatment
Lead Sponsor:
Institut de Radioprotection et de Surete Nucleaire
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Aim/Introduction: The treatment of differentiated thyroid cancer includes generally a total thyroidectomy, followed by a radioiodine (131I)-therapy. Due to their ability to concentrate iodine, the sa...
Eligibility Criteria
Inclusion
- treated for differencied thyroid cancer
- aged of 18 and more
Exclusion
- having been treated by chemiotherapy or radiotherapy
- no French language
- can't be follow at 6 months after treatment
Key Trial Info
Start Date :
September 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 26 2021
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT04876287
Start Date
September 2 2020
End Date
April 26 2021
Last Update
May 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié-Salpêtrière hospital
Paris, France, 75013